Q1 EPS Forecast for Arcus Biosciences Decreased by Analyst

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($1.13) per share for the quarter, down from their prior forecast of ($0.89). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($1.72) EPS and FY2028 earnings at $1.06 EPS.

A number of other research firms also recently weighed in on RCUS. Morgan Stanley dropped their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $18.00 to $24.00 in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Bank of America lowered their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Arcus Biosciences presently has an average rating of “Buy” and a consensus price target of $30.25.

Arcus Biosciences Price Performance

RCUS opened at $9.87 on Friday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $1.04 billion, a P/E ratio of -3.13 and a beta of 0.84. The stock has a 50-day moving average price of $13.46 and a 200-day moving average price of $15.42. Arcus Biosciences has a 12-month low of $9.85 and a 12-month high of $20.10.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Terry J. Rosen acquired 19,800 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, with a total value of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in shares of Arcus Biosciences in the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences in the 3rd quarter worth approximately $47,000. Lazard Asset Management LLC grew its stake in shares of Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after acquiring an additional 6,078 shares during the last quarter. US Bancorp DE grew its position in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares during the last quarter. Finally, Quest Partners LLC increased its position in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.